Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma
Feiyue Xu(Foshan University), Yangchao Chen(Guangzhou University of Chinese Medicine), Chi Hin Wong(Chinese University of Hong Kong), Shengwen Shao(Huzhou Normal University), George Y. Chen(Chinese University of Hong Kong), Paul B.S. Lai(Chinese University of Hong Kong), Chi Han Li(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong)
Cited by 40
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k